You are on page 1of 34

A Novel Therapeutic Strategy to Address Cancer

September 2011


is the leading cause of death worldwide and accounted for 7.6 million deaths in 2008 alone

There were 12.7 million new cases of

Cancer in 2008

Cancer deaths in the United States
are expected to exceed 570,000 in 2011

In 2011, new cases of Cancer are expected to exceed 1,500,000 in the U.S.

Innovative strategies are needed to address Cancer progression mechanisms that are beyond the reach of current drug therapies

A therapeutic strategy that could inhibit the proliferation of immunosuppressive exosomes released by solid tumors, lymphomas and leukemias would fill a significant unmet medical need in cancer care

What are Exosomes?

• Cancer cells, both in vivo and in vitro, have been demonstrated to release membranous structures, defined as exosomes

Researchers have recently unveiled several roles that exosomes play in accelerating cancer progression

The resulting research publications are reporting that................

Exosomes cause apoptosis or programmed cell death of immune cells

Exosomes disrupt signaling of anti-cancer T cells

Exosomes contribute to tumor angiogenesis

Exosomes enhance the spread of tumor metastasis

The quantity of exosomes in circulation is in direct correlation with cancer progression

What if exosomes could be eliminated from circulation?

The Aethlon Hemopurifier®
The first therapeutic candidate to eliminate cancer exosomes from circulation

The Aethlon Hemopurifier®
• Provides a therapeutic filtration mechanism to remove cancer exosomes from the circulatory system • Allows selective exosome capture via unique high-mannose signatures resident on exosome surfaces

Providing access to the entire circulatory system

• Exosomes can be accessed from entire circulatory system, which can pass through the Hemopurifier® in as little as 15 minutes

Hemopurifier® therapy has the advantage of being delivered through the global infrastructure of dialysis machines that are already located in hospitals in clinics

Our goal is to improve patient responsiveness to traditional chemotherapies and emerging classes of immune based therapies

To improve patient responsiveness without additional drug toxicity or interaction risks

In vitro binding of exosomes underlying the following cancers has been demonstrated

• Breast • Ovarian • Colorectal • Lymphoma • Melanoma

Human Hemopurifier® treatment experience already exists

The Hemopurifier® has previously demonstrated the ability to reduce viral load in HIV and hepatitis C (HCV) infected individuals without the administration of antiviral drugs

A clinical study to evaluate the ability of the Hemopurifier® to improve HCV drug therapy benefit is currently being conducted

The clinical application of the Hemopurifier® in Cancer?

We are currently collaborating with candidate investigators to develop a clinical protocol to demonstrate the ability of our Hemopurifier® to eliminate circulating cancer exosomes

We invite you to follow our efforts to improve cancer care

Our mission is to create innovative devices that
address unmet medical needs in cancer, infectious disease, and other life-threatening conditions

Thank You

Jim Joyce Chairman, CEO 8910 University Center Lane San Diego, California 92122

  This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements be subject to the safe harbor created thereby.   These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including the company’s ability to successfully obtain FDA and other regulatory approvals for the sale of its products, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, and the company’s ability to raise capital when needed.     Some information in this presentation, or on which this presentation is based, has been obtained from sources that Aethlon Medical, Inc., believes to be reliable and accurate.   However, it has not been independently verified and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information obtained from third parties.   Such risks and uncertainties, including those discussed above, are more fully described in the Securities and Exchange Commission (SEC) reports filed by Aethlon Medical, Inc., including its most recent annual report on Form 10-K. This presentation speaks only as of its date, and the company disclaims any duty to update the information herein. Further information is available by contacting the company or at the company’s website at